These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32873831)

  • 1. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
    Liu Y; Hou HA; Qiu H; Tang CH
    Sci Rep; 2020 Sep; 10(1):14393. PubMed ID: 32873831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
    Giri S; Barth P; Costa LJ; Olszewski AJ
    J Geriatr Oncol; 2021 Mar; 12(2):256-261. PubMed ID: 32684352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
    Jones JR; Cairns DA; Gregory WM; Collett C; Pawlyn C; Sigsworth R; Striha A; Henderson R; Kaiser MF; Jenner M; Cook G; Russell NH; Williams C; Pratt G; Kishore B; Lindsay J; Drayson MT; Davies FE; Boyd KD; Owen RG; Jackson GH; Morgan GJ
    Blood Cancer J; 2016 Dec; 6(12):e506. PubMed ID: 27935580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of secondary primary malignancies after therapy for multiple myeloma.
    Areethamsirikul N; Reece DE
    Leuk Lymphoma; 2015; 56(11):3012-21. PubMed ID: 25947036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
    Rollison DE; Komrokji R; Lee JH; Hampras S; Fulp W; Fisher K; Baz R; Nishihori T; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Sullivan D; Alsina M; Dalton W; Shain KH
    Leuk Lymphoma; 2017 Mar; 58(3):560-568. PubMed ID: 27424609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
    Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL
    Lancet Oncol; 2014 Mar; 15(3):333-42. PubMed ID: 24525202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
    Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
    Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
    Liu Y; Tang CH; Qiu H; Siggins S; Hou HA
    Sci Rep; 2021 Jan; 11(1):1112. PubMed ID: 33441901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second primary malignancy after multiple myeloma-population trends and cause-specific mortality.
    Costa LJ; Godby KN; Chhabra S; Cornell RF; Hari P; Bhatia S
    Br J Haematol; 2018 Aug; 182(4):513-520. PubMed ID: 29974936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
    Saleem K; Franz J; Klem ML; Yabes JG; Boyiadzis M; Jones JR; Shaikh N; Lontos K
    Lancet Haematol; 2022 Dec; 9(12):e906-e918. PubMed ID: 36354020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
    Dimopoulos MA; Richardson PG; Brandenburg N; Yu Z; Weber DM; Niesvizky R; Morgan GJ
    Blood; 2012 Mar; 119(12):2764-7. PubMed ID: 22323483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
    Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
    N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan: A Nationwide Population-Based Study.
    Teng CJ; Huon LK; Hu YW; Yeh CM; Chao Y; Yang MH; Chen TJ; Hung YP; Liu CJ
    Medicine (Baltimore); 2015 Oct; 94(43):e1803. PubMed ID: 26512575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden.
    Nahi H; Walinder G; Patel V; Qu Y; Levine A; Majer I; Kutikova L; Hellqvist Franck E; Svensson MK; Hansson M
    Acta Haematol; 2021; 144(5):519-527. PubMed ID: 33631745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
    Rifkin RM; Abonour R; Shah JJ; Mehta J; Narang M; Terebelo H; Gasparetto C; Toomey K; Hardin JW; Lu JJ; Kenvin L; Srinivasan S; Knight R; Nagarwala Y; Durie BG
    Leuk Lymphoma; 2016 Sep; 57(9):2228-31. PubMed ID: 26766599
    [No Abstract]   [Full Text] [Related]  

  • 18. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
    Engelhardt M; Ihorst G; Landgren O; Pantic M; Reinhardt H; Waldschmidt J; May AM; Schumacher M; Kleber M; Wäsch R
    Haematologica; 2015 Oct; 100(10):1340-9. PubMed ID: 26160877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second primary malignancies in multiple myeloma: A review.
    Poh C; Keegan T; Rosenberg AS
    Blood Rev; 2021 Mar; 46():100757. PubMed ID: 32972803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second primary malignancy risk after radiotherapy in rectal cancer survivors.
    Wang TH; Liu CJ; Chao TF; Chen TJ; Hu YW
    World J Gastroenterol; 2018 Oct; 24(40):4586-4595. PubMed ID: 30386108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.